Strategic focus shifted to PAYDAY, with Project Baxter discontinued and a major impairment recorded. Q3 net sales grew year-over-year, but profitability was impacted by high direct costs and impairments. Cash flow improved, and the outlook emphasizes live operations, platform expansion, and partnerships.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.